An interventional study of Exercise and Exercise in Parkinson Disease (PD), sponsored by The University of New South Wales. Recruiting at 1 site in Australia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-17.
Sponsored by The University of New South Wales · Not applicable, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 59 studies in Parkinson Disease with a site in Australia — 10 open to participants now, 12 under way, 3 of them phase 3. Parkinson Disease · Australia.
Among the 59 studies in Parkinson Disease with a site in Australia, this one is the 43rd largest by planned enrollment of the 54 interventional ones that give a count, is one of 4 that started in 2025, is one of 5 with no phase, reaches primary completion later than 3 of the 11 other live ones, and was the 55th registered.
4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.
Browse Parkinson Disease studies →10 of the 59 studies in Parkinson Disease with a site in Australia are open now. Recruiting first, the newest first:
Serina Therapeutics · Sites in Australia, United States, Taiwan
Ages 40–80
Hoffmann-La Roche · Sites in Australia, United States, Austria and 14 more countries
Ages 50–85
BlueRock Therapeutics · Sites in Australia, United States, Canada
Ages 45–75
Gain Therapeutics, Inc. · Sites in Australia
Ages 30–85
Longevity Biotech Australia Pty Ltd (subsidiary) · Sites in Australia
Ages 30–89 · Healthy volunteers
A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →
Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
59 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 12 · Phase 3 28 · Phase 4 2
First in 2002; this study’s year is marked. 4 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 42 is close to the median of 40 across 3,360 interventional studies indexed under Parkinson Disease.
Median enrollment 132 across the 54 interventional studies, 234 across the 5 observational. Of the 43 that completed or were terminated, 20 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
48 of 59 have an industry lead sponsor. The 10 most frequent:
The University of New South Wales is the lead sponsor of 66 studies on the registry; 6 are open to participants now.
The University of New South Wales has 1 study filed under Parkinson Disease — fewer than ten, so there is no comparison to draw.
3 of the studies in Parkinson Disease with a site in Australia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07422675Serina TherapeuticsSAD Study in Patients With Parkinson's Disease and Motor Fluctuations | 2027-01-31 |
| NCT06466525Longevity Biotech Australia Pty Ltd (subsidiary)A Two-Part Single and Multiple Ascending Dose Trial of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LBT-3627 in Healthy Participants and in Participants With Parkinson's Disease. | 2027-02 |
| NCT07630545Mission TherapeuticsA Phase I Study in Healthy Volunteers and Parkinson's Disease (PD) Patients. | 2027-06-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 59 studies in Parkinson Disease with a site in Australia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Parkinson's Disease Treadmill Training RCT Summary
Parkinson's disease (PD) affects over 10 million people globally. Despite optimal pharmacological treatment, approximately 70% of individuals experience unstable gait and falls, leading to loss of confidence, social isolation, fractures, and frequent hospitalisations. Treadmill training-especially when augmented by mechanical or virtual-reality perturbations-has shown promise in improving gait and reducing fall risk. However, the mechanisms underlying these benefits remain poorly understood, limiting the ability to personalise interventions effectively.
This randomised controlled trial (RCT) forms part of the broader Steps Against the Burden of Parkinson's Disease project (CT-IDs: 6ef2e427b002, 6ef2e427b003, 6ef2e427b004), comprising three harmonised but independently conducted RCTs. All sites follow a shared core protocol, allowing for pooled data analysis while preserving site-specific perturbation adaptations. Findings from this trial will be reported both independently and as part of the combined dataset.
In this trial, participants with PD will undergo 12 sessions of treadmill training, with or without virtual reality and perturbation-based adaptations. Assessments will be conducted at baseline, post-training, and follow-up. The intervention aims to enhance gait through improved sensorimotor integration and balance control. During the follow-up period, a smartphoneapp "Walking Tall" will be used to encourage continued exercises and long-term retention of training effects.
Biomechanical analyses will focus on changes in foot placement control. Neurophysiological outcomes will be examined using EEG and EMG, targeting reductions in beta-band EEG power and enhanced EEG-EMG coherence as markers of improved gait stability.
Recognising that laboratory-based improvements may not always translate to daily life, this study will also investigate gait self-efficacy as a potential moderator of transfer. Remote monitoring tools will capture real-world mobility outcomes over a week. Machine learning techniques will be employed to identify factors differentiating those who improve in both settings from those who do not. These insights will inform the development of personalised interventions capable of translating training effects into meaningful real-life outcomes.
i. Rationale The rationale of this trial is that speed-dependent treadmill training (SDTT) improves gait in people with Parkinson's disease (PD) through enhanced sensorimotor integration, with cortical activity changes as underlying neural correlates. Additional benefits may be gained when treadmill training includes perturbations, which help train reactive balance responses. Furthermore, it is hypothesised that improvements in gait quality through SDTT can enhance gait self-efficacy, which may mediate or moderate the transfer of training effects to everyday mobility. Understanding these mechanisms is essential for personalising interventions and maximising real-world outcomes.
ii. Objectives
The objectives of the StepuP project are to:
Achieving these objectives will advance understanding of the variability in individual response to treadmill training, allowing more targeted and ultimately personalised interventions to improve outcomes in PD.
iii. Endpoints This trial will evaluate the effects of treadmill training with and without perturbations on gait performance and neural correlates in people with PD.
Primary endpoint:
> Change in gait speed under controlled treadmill conditions.
Secondary endpoints:
Exploratory endpoints:
These outcomes will help identify how and for whom treadmill training leads to meaningful, lasting improvements in mobility.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
SDTT adjusts the treadmill's speed in real time to match an individual's walking pace, creating a dynamic and adaptive training environment. This approach simulates real-world walking conditions, promoting neuromuscular coordination, balance, and functional mobility. By tailoring speed to the user's natural gait, SDTT supports the development of efficient and more natural walking patterns. It has shown promise across clinical populations, including those with neurological disorders, musculoskeletal conditions, or recovering from injury. Its flexibility allows for progressive challenge as walking ability improves, making SDTT a valuable tool for optimising gait and mobility outcomes.
Other: Exercise
The SDTT+ program combines speed-dependent treadmill training with perturbations and VR-triggered adaptations. Reactive gait responses are elicited through controlled accelerations and decelerations of treadmill belts, simulating real-life balance challenges.
Other: Exercise
SDTT adjusts the treadmill's speed in real time to match an individual's walking pace, creating a dynamic and adaptive training environment. This approach simulates real-world walking conditions, promoting neuromuscular coordination, balance, and functional mobility. By tailoring speed to the user's natural gait, SDTT supports the development of efficient and more natural walking patterns. It has shown promise across clinical populations, including those with neurological disorders, musculoskeletal conditions, or recovering from injury. Its flexibility allows for progressive challenge as walking ability improves, making SDTT a valuable tool for optimising gait and mobility outcomes.
Also known as: SDTT, Treadmill training, Gait training
The SDTT+ program combines speed-dependent treadmill training with perturbations and VR-triggered adaptations. Reactive gait responses are elicited through controlled accelerations and decelerations of treadmill belts, simulating real-life balance challenges.
Also known as: SDTT+, VR, perturbation training, Treadmill training, Gait training
Gait speed
Comfortable walking speed overground
Time frame: Baseline (week 1), Post-Training (week 14), Follow-up (week 26)
Fall Events
The number of falls experienced and whether they resulted in injury will be recorded. This includes a 12-month retrospective report at baseline and ongoing reporting throughout the study.
Time frame: Retrospective report at Baseline (week 1); ongoing reporting through Follow-up (week 26).
EuroQol 5-Dimension (EQ-5D) Questionnaire
This quality-of-life instrument includes a descriptive profile and a visual analogue scale (VAS) to rate current health. The VAS ranges from 0 (the worst health imaginable) to 100 (the best health imaginable). Higher scores on the VAS indicate better health status.
Time frame: Baseline (week 1), Post-Training (week 14), Follow-up (week 26).
Frailty Index (FI)
The Frailty Index assesses physical frailty based on five criteria: shrinking (unintentional weight loss), low physical endurance or energy (self-reported exhaustion), low physical activity, weakness (grip strength), and slow walking speed. Based on the number of criteria met (0 to 5), participants are classified into the following categories: Non-frail (0 criteria met) Pre-frail (1-2 criteria met) Frail (3 or more criteria met)
Time frame: Baseline (week 1), Post-Training (week 14), Follow-up (week 26).
FACIT Fatigue Scale (Functional Assessment of Chronic Illness Therapy - Fatigue)
The FACIT Fatigue Scale measures self-reported fatigue and its impact on daily activities and functioning over the past week. Each item is scored on a 5-point Likert scale ranging from 0 ("Not at all") to 4 ("Very much"). Total Score Range: 0 to 52. Higher scores indicate less fatigue and better functioning.
Time frame: Baseline (week 1), Post-Training (week 14), Follow-up (week 26).
Visual Analogue Scale (VAS)
The VAS is used to assess subjective pain intensity or other symptom severity.
Time frame: Baseline (week 1), Post-Training (week 14), Follow-up (week 26).
Foot placement kinematics
Three-dimensional motion capture will be used to evaluate gait and movement patterns, specicially the foot placement in relation to the centre of mass.
Time frame: Baseline (week 1), Post-Training (week 14), Follow-up (week 26).
Timed Up and Go (TUG)
The TUG test assesses mobility, balance, and walking ability.
Time frame: Baseline (week 1), Post-Training (week 14), Follow-up (week 26).
Two-Minute Walk Test (2MWT)
This test measures functional exercise capacity by recording the distance walked in two minutes.
Time frame: Baseline (week 1), Post-Training (week 14), Follow-up (week 26).
Mini-BESTest
The Mini-BESTest evaluates dynamic balance across multiple domains of postural control.
Time frame: Baseline (week 1), Post-Training (week 14), Follow-up (week 26).
Modified Gait Efficacy Scale (mGES)
The mGES measures confidence in walking under challenging everyday conditions.
Time frame: Baseline (week 1), Post-Training (week 14), Follow-up (week 26).
Short Falls Efficacy Scale International (Short FES-I)
The Short Falls Efficacy Scale International is a 7-item questionnaire assessing concern about falling during a range of physical and social activities. Each item is scored from 1 (not at all concerned) to 4 (very concerned), resulting in a total score ranging from 7 to 28. Higher scores indicate greater concern about falling, which reflects a worse outcome.
Time frame: Baseline (week 1), Post-Training (week 14), Follow-up (week 26).
Montreal Cognitive Assessment (MoCA)
The MoCA evaluates cognitive function, including memory, attention, language, and executive functions. The MoCA consists of 30 points, with scores ranging from 0 to 30. Higher scores indicate better cognitive function, reflecting a better outcome.
Time frame: Baseline (week 1), Follow-up (week 26).
Color Trail Test (CTT)
The CTT assesses cognitive flexibility, visual attention, and processing speed. The CTT consists of two parts (CTT-1 and CTT-2), where participants are required to connect numbered circles in sequence, alternating between colours in the second part. Performance is measured by the time (in seconds) taken to complete each part. shorter completion times indicate better cognitive function, reflecting a better outcome.
Time frame: Baseline (week 1), Follow-up (week 26).
Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS Part III)
The MDS-UPDRS Part III is the motor examination component of the Unified Parkinson's Disease Rating Scale developed by the Movement Disorder Society. It assesses motor signs of Parkinson's disease across 18 items (e.g., tremor, rigidity, bradykinesia, posture, gait), each rated on a 5-point scale from 0 (normal) to 4 (severe impairment). The total score ranges from 0 to 132. Higher scores indicate greater motor impairment, reflecting a worse outcome.
Time frame: Baseline (week 1), Post-Training (week 14), Follow-up (week 26).
New Freezing of Gait Questionnaire (NFOGQ)
The NFOGQ is a 9-item patient-reported instrument designed to assess the presence, severity, and impact of freezing of gait (FOG) in individuals with Parkinson's disease. Items are scored on a 5-point Likert scale ranging from 0 (absence or no impact) to 4 (severe or frequent impact). The total score ranges from 0 to 28, with higher scores reflecting more severe and frequent freezing episodes. Higher scores indicate worse freezing of gait symptoms, representing a worse outcome.
Time frame: Baseline (week 1), Post-Training (week 14), Follow-up (week 26).
Daily Step Count
The average number of steps taken per day will be recorded via wearable sensors.
Time frame: Baseline (week 1), Post-Training (week 14), Follow-up (week 26).
Uninterrupted Walking Duration
Duration of uninterrupted walking bouts will be measured using wearable sensors.
Time frame: Baseline (week 1), Post-Training (week 14), Follow-up (week 26).
Stride Time Variability
Stride-to-stride variability in walking rhythm will be derived from sensor data.
Time frame: Baseline (week 1), Post-Training (week 14), Follow-up (week 26).
Gait Symmetry
The symmetry of gait parameters between left and right limbs will be calculated.
Time frame: Baseline (week 1), Post-Training (week 14), Follow-up (week 26).
System Usability Scale (SUS)
Participants' acceptability and satisfaction with the intervention will be assessed via the SUS. The SUS is a 10-item questionnaire that assesses user satisfaction and perceived usability of a system or intervention. Each item is rated on a 5-point Likert scale from 1 (strongly disagree) to 5 (strongly agree). Raw item scores are converted to a composite score ranging from 0 to 100. Higher scores indicate better perceived usability and greater user satisfaction, reflecting a better outcome.
Time frame: Post-Training (week 14), Follow-up (week 26).
Physical Activity Enjoyment Scale (PACES)
Participants' acceptability and satisfaction with the intervention will be assessed via the PACES. The PACES is an 18-item questionnaire designed to assess enjoyment of physical activity. Each item is rated on a 7-point Likert scale (e.g., from "I enjoy it" to "I hate it"), with some items reverse-scored. The total score ranges from 18 to 126, with higher scores indicating greater enjoyment of physical activity, reflecting a better outcome.
Time frame: Post-Training (week 14), Follow-up (week 26).
Attitudes Towards Physical Activity
The Exercise Self-Efficacy Scale (ESES) will assess changes in attitudes toward physical activity. The ESES is a 10-item questionnaire that assesses confidence in engaging in physical activity despite common barriers. Each item is rated from 1 (not at all confident) to 4 (always confident). Total scores range from 10 to 40. Higher scores indicate greater confidence in the ability to exercise, reflecting a better outcome.
Time frame: Post-Training (week 14), Follow-up (week 26).
Participant experience
Semi-structured qualitative interviews will explore participant experiences, perceived barriers, enablers, and reasons for withdrawal. As this is a qualitative assessment, no numerical scale applies, and responses will be analysed using thematic analysis methods.
Time frame: Post-Training (week 14), Follow-up (week 26).
Beta band activity
EEG (electroencephalogram) will be used to measure brain activity by recording electrical signals from the scalp. It will assess beta band activity during walking to examine changes in cortical involvement associated with gait and training.
Time frame: Baseline (week 1), Post-Training (week 14), Follow-up (week 26).
EEG-EMG coherency in the beta band
Coherency between EEG and EMG signals in the beta frequency band will be assessed during walking to evaluate changes in corticomuscular connectivity associated with gait and training.
Time frame: Baseline (week 1), Post-Training (week 14), Follow-up (week 26).
Fracture History
The number and type of fractures sustained in the 12 months prior to baseline will be recorded.
Time frame: Baseline (week 1).
Changes in medication
All current medications (including antiparkinsonian and non-antiparkinsonian drugs) will be recorded at each study visit to monitor changes in use and assess potential side effects. Changes in medication will be categorised (e.g., dosage adjustments), and the number of participants with any change in medication will be reported.
Time frame: Baseline (week 1), Post-Training (week 14), Follow-up (week 26).
Number of participants using mobility aids (indoors and outdoors)
The use of mobility aids (e.g., cane, walker, rollator) will be documented separately for indoor and outdoor environments. The number and percentage of participants using walking aids will be reported at each time point.
Time frame: Baseline (week 1), Follow-up (week 26).
Hand Grip Strength
Grip strength will be assessed using a hand dynamometer as a proxy for overall strength and frailty.
Time frame: Baseline (week 1).
Plan to share: Yes — The pseudonymized personal dataset corresponding to study participants who have opted in at the time of consent
Time frame: The pseudonymized personal dataset corresponding to study participants who have opted in at the time of consent will be made available within two years of study completion
Access criteria: Researchers comply with applicable data protection law, particularly Chapter V of the GDPR and the recommendations of the European Data Protection Board. Researchers submit an approved data management and intended use plan. Researchers approved by all sites including the University of New South Wales Human Research Ethics Committee.
Data sharing details ↗ · openneuro.org
No publications or documents are linked to this record.
Started Jul 2025 (actual). Primary completion is estimated for Sep 2026, 14 months after the start.
Of 1,297 non-industry interventional studies with no phase under Parkinson Disease, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's planned 14 months is below that.
Counting every sponsor, half of 1,373 studies reached it within 25 months; a quarter within 11 and three quarters within 44.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
The University of New South Wales